National emergencies, like the one COVID-19 has triggered in the United States, spur technological development, as concerned researchers look for ways to repurpose existing technology or develop new technology to help. ...more
Every year, the National Institutes of Health (NIH) spends billions of federal dollars on research and development of new drugs and therapies for treating and preventing serious illnesses....more
3/27/2018
/ Failure to Report ,
Federal Funding ,
Gilead Sciences ,
Inventions ,
Life Sciences ,
National Institute of Health (NIH) ,
Patent Ownership ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
R&D ,
Reporting Requirements ,
Research and Development ,
Scientific Research
Patent protection can be critical for health care products, including medical devices, prescription drugs, dietary supplements and software as a medical device (SaMD).
Originally published in Law360 - September 8, 2017....more
The prevalence of inter partes reviews (and post-grant reviews to come) forces practitioners to consider the strong likelihood that patents covering commercial products will face post-grant challenges.
Originally...more